ASX healthcare sector, after reaching a high in January end had been run down till April beginning. Since then, it has kept resurging. From ASX listed companies, a few stand out for their long term potential. The growing companies to invest in are
Dimerix Limited (ASX: DXB)
Dimerix Limited, a clinical-stage biopharma company based in Australia, continues to progress its goal of developing novel treatments for rare inflammatory conditions. Its lead asset, DMX-200, is under evaluation in a pivotal Phase 3 clinical trial, titled ACTION3, for the treatment of Focal Segmental Glomerulosclerosis (FSGS) - a rare kidney disease that currently has no FDA-approved treatments. The company’s global trial footprint has expanded significantly, with the first clinical site in Japan now activated, marking a major milestone that triggered a ¥400 million development payment from FUSO Pharmaceutical Industries. This milestone followed a key regulatory validation, as the U.S. FDA acknowledged that using a proteinuria-based endpoint is suitable for securing full marketing approval of DMX-200. As of now, 183 patients have been dosed in the trial, which continues unchanged following six successful safety reviews by an independent monitoring committee. Further reinforcing the program’s momentum, Dimerix secured an upfront payment of US$30 million through a U.S. licensing deal with Amicus Therapeutics.
Dimerix, one of the top growth stocks, builds its global commercial framework, HAVING secured four major regional licensing deals with FUSO, Amicus, Advanz Pharma, and Taiba, collectively worth up to A$1.4 billion in potential upfront and milestone payments, plus royalties. With A$17.0 million in cash as of 31 March 2025, the company is well-funded, not accounting for upcoming milestone inflows. Looking ahead, full enrolment of the ACTION3 trial is expected by the end of 2025. Dimerix continues to draw strong partnership interest in unlicensed territories, driven by its clinical progress and clear regulatory pathway. As it marches towards potential regulatory submissions and commercial rollout, Dimerix is positioning itself as a global leader in addressing the critical unmet needs of FSGS patients.
Neuren Pharmaceuticals (ASX: NEU)
Neuren Pharmaceuticals, among the best growth stocks to buy now is reshaping the landscape of neurological disorder treatment with its science-driven innovation and strong commercial execution. The company's flagship therapy, DAYBUE™ (trofinetide), has cemented its place in history as the first-ever FDA- and Health Canada-approved treatment for Rett syndrome. Since its U.S. launch in April 2023 by partner Acadia Pharmaceuticals, DAYBUE has delivered outstanding results—net sales reached US$348 million in 2024 alone, generating A$56 million in royalties for Neuren. These sales exceeded the US$250 million milestone, earning Neuren an additional A$80.5 million payment. Neuren also received A$76.5 million as its one-third share of a US$150 million sale of a Priority Review Voucher granted to Acadia. This performance underpinned a record A$166 million in total comprehensive income for 2024 and left the company with A$341 million in cash and short-term investments at 31 March 2025. Acadia’s DAYBUE U.S. net sales guidance for 2025 stands at US$380–405 million, with anticipated royalties to Neuren of A$62–67 million.
As DAYBUE expands globally, Neuren is simultaneously preparing its next breakthrough. NNZ-2591, the company’s second drug candidate, showed positive Phase 2 results across three indications: Phelan-McDermid, Pitt Hopkins, and Angelman syndromes. In 2025, Neuren plans to begin a pivotal Phase 3 trial in Phelan-McDermid syndrome, having already aligned with the FDA on trial design and endpoints. The trial is fully funded and expected to involve 160 children. Meanwhile, Neuren is advancing NNZ-2591 into new frontiers, including hypoxic-ischemic encephalopathy (HIE), with plans for a pre-IND meeting with the FDA later in 2025. With strong clinical validation, global commercial partnerships, and a robust cash position, Neuren stands poised for a transformative future in neurological drug development.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
